Compugen (CGEN) EBITDA (2009 - 2026)

Compugen (CGEN) has 18 years of EBITDA data on file, last reported at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 7.41% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $31.9 million (up 313.16% YoY), and the FY2025 full-year result was $31.3 million, up 310.37% from the prior year.
• EBITDA fell to $9.0 million in Q1 2026, from $56.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $56.0 million in Q4 2025 to a low of -$30.5 million in Q2 2023.
• A 5-year average of $916058.8 and a median of -$3.5 million in 2022 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 848.94% in 2025, while the deepest fall reached 275.56% in 2025.
• Tracing CGEN's EBITDA over 5 years: stood at -$3.5 million in 2022, then surged by 609.61% to $18.0 million in 2023, then slumped by 141.61% to -$7.5 million in 2024, then surged by 848.94% to $56.0 million in 2025, then sank by 83.91% to $9.0 million in 2026.
• Business Quant data shows CGEN's EBITDA at $9.0 million in Q1 2026, $56.0 million in Q4 2025, and -$7.9 million in Q3 2025.